CSL, ranking first on the list of the largest biotech companies in Australia, is a worldwide expertise biotechnology firm based in Australia that conducts research, develops, produces, and distributes medicines to treat and prevent serious human medical conditions. CSL's product lines include blood plasma derivatives, vaccines, antivenom, and cell culture reagents for use in medical and genetic research and production.

With over 32,000 employees globally, it offers life-saving medications in more than 60 countries. CSL is driven to develop and supplies a wide variety of life-saving medications for diseases such as hemophilia and primary immunological deficiencies, as well as influenza vaccinations. Its treatments are also used in cardiac surgery, organ transplantation, and burn care.

The organization is committed to innovation, as evidenced by the 1,100 devoted scientists who work every day to meet the unmet needs of patients. CSL collaborates and supports patient and medical communities as a worldwide leader by expanding access to medicines, promoting scientific knowledge, supporting future medical researchers, and engaging its employees in community service.

Founded: 1916
Headquarters: Parkville, Melbourne, Victoria, Australia
Webiste: https://www.csl.com/

Mesoblast is a biotechnology company that is developing and commercializing allogeneic cellular therapeutics to treat serious and life-threatening inflammatory diseases with high unmet medical needs.

The following are the Company's Phase 3 off-the-shelf mesenchymal lineage cell product candidates:

• RYONCIL (remestemcel-L) is used to treat steroid-resistant acute graft versus host disease (acute GVHD).
• Remestemcel-L for COVID-19 infection-related mild to severe acute respiratory distress syndrome (ARDS).
• REVASCOR is used to treat advanced chronic heart failure, while MPC-06-ID is used to treat chronic low back pain caused by degenerative disc degeneration.

Mesoblast's product development strategy is to conduct rigorous scientific studies using well-characterized cell populations in order to identify mechanisms of action for each potential application. Mesoblast has an extensive patent portfolio that includes over 1,000 patents and patent applications with protection in all key markets through 2040. This intellectual property portfolio includes mesenchymal lineage cell composition, production, and medicinal uses.

Founded: 2004

Headquarters: Melbourne, VIC, Australia

Website: https://www.mesoblast.com/

Opthea is the next name on the list of the largest biotech companies in Australia, it is a clinical-stage biopharmaceutical firm dedicated to finding innovative therapies to help people with retinal diseases enhance their visual function. Millions of people worldwide have poor vision as a result of diabetes and old age. The company's objective is to enhance eyesight so that people may live better lives.

In the first part of 2021, Opthea began two key Phase 3 clinical studies for the treatment of wet AMD. Opthea has completed three worldwide clinical studies in which OPT-302 was tested in two disease indications. Two of the studies were in wet AMD patients, including the first in a human Phase 1b/2a study, followed by a major randomized controlled Phase 2b study, and the third was in DME patients.

OPT-302, its first-in-class novel therapy, is a VEGF-C/D 'trap' that be utilized in combination with existing standard-of-care anti-VEGF-A medications to enhance vision in patients. It has the potential to address an unmet medical need in individuals with wet age-related macular degeneration (AMD) and diabetic macular edema (DME), many of whom respond suboptimally or develop resistance to conventional treatments for these debilitating diseases.

Founded: 2012

Headquarters: South Yarra, VIC, Australia

Website: https://opthea.com/

Immutep is a multinational biotechnology business that is a pioneer in the development of LAG-3-related immunotherapeutic medicines for cancer and autoimmune disease therapy. Immutep is committed to maximizing shareholder value by utilizing its technology and experience to bring breakthrough therapeutic solutions to the market for patients.

Immutep has been a pioneer in developing treatments to either activate or inhibit the immune system in order to fight cancer or get rid of autoimmune diseases. It now has a diverse portfolio of cutting-edge immuno-oncology and targeted LAG-3 immunotherapy prospects, comprising three clinical-stage candidates, one pre-clinical candidate, and one early-stage candidate.

Immutep's current lead product candidate is eftilagimod alpha (efti or IMP321), a soluble LAG-3 fusion protein (LAG-3Ig) that is being studied in cancer and infectious diseases. Immutep is also working on a LAG-3 agonist (IMP761) for autoimmune disease. Immutep's significant pharmaceutical partners are developing other LAG-3 medicines, including antibodies for immune response modulation.

Founded: 2001

Headquarters: Sydney, NSW, Australia

Website: https://www.immutep.com/

End of the list of the largest biotech companies in Australia is Incannex Healthcare. It is a clinical-stage pharmaceutical development company focused on the development of novel medicinal cannabis pharmaceutical products and psychedelic medicine therapies for the treatment of anxiety disorders, obstructive sleep apnea (OSA), traumatic brain injury (TBI)/concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, and inflammatory bowel disease.

As it develops its products and therapies in collaboration with its medical and scientific advisory board and partners, Incannex has a strong patent filing strategy in place. It has a diverse portfolio of 28 unique research and development (R&D) activities, 6 clinical trials now active, and more planned.

Its objective is to alleviate human suffering by developing innovative and ethical medications and therapies for patients with unmet medical needs, utilizing compounds and delivery systems with strong pre-existing scientific effectiveness evidence. The company is pursuing FDA registration and marketing approval for each product and therapy under development.

Founded: 2015

Headquarters: Melbourne, VIC, Australia

Website: https://www.incannex.com/